<DOC>
	<DOCNO>NCT00681005</DOCNO>
	<brief_summary>Backgrounds &amp; Aims : Proton-pump inhibitor ( PPI ) test propose valuable tool diagnosis gastroesophageal reflux disease ( GERD ) Western population . We assume high prevalence poor metabolizers Chinese population might affect diagnostic accuracy PPI test . Methods : In open-label , randomize trial , patient symptoms suggestive GERD randomly assign receive 2-week test daily rabeprazole 40-mg daily pantoprazole 80-mg diagnostic endoscopy . Therapeutic response assess five-grade daily record . Genotypes cytochrome P450 ( CYP ) 2C19 polymorphism determine .</brief_summary>
	<brief_title>A Comparative Study Proton-pump Inhibitor Tests Chinese Reflux Patients Relation CYP2C19 Genotypes</brief_title>
	<detailed_description>As described</detailed_description>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<criteria>Consecutive patient symptom suggest GERD enrol gastroenterology outpatient clinic academic institute . The typical GERD symptom define heartburn and/or regurgitation least 3 episode per week recent 3 month . Those maintenance PPI treatment , medical contraindication PPI therapy , report history peptic ulcer disease gastrointestinal surgery , malignancy proven endoscopy , unwilling unable provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>PPI test</keyword>
	<keyword>gastroesophageal reflux disease</keyword>
	<keyword>CYP2C19</keyword>
	<keyword>rabeprazole</keyword>
	<keyword>pantoprazole</keyword>
</DOC>